A new approach : Valproic acid in Huntington ’ s Disease

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Benefit of valproic acid in suppressing disease progression of ALS model mice

  2005cited by this paper
• Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia.

  2005cited by this paper
• Mood-stabilizing drugs: are their neuroprotective aspects clinically relevant?

  2005cited by this paper
• Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neurons

  2004cited by this paper
• Congruent deterioration of complex and simple movements in patients with Huntington's disease.

  2004cited by this paper
• Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases?

  2004cited by this paper
• [Cortical reflex myoclonus in adult onset Huntington's disease].

  2004cited by this paper
• Valproate is Neuroprotective against Malonate Toxicity in Rat Striatum: An Association with Augmentation of High-Affinity Glutamate Uptake

  2004cited by this paper
• Valproate inhibits oxidative damage to lipid and protein in primary cultured rat cerebrocortical cells.

  2003cited by this paper
• Assessment of complex movements reflects dysfunction in Huntington’s disease

  2003cited by this paper
• Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition

  2003cited by this paper
• Neuroprotective properties of valproate

  2002cited by this paper
• Valproate and neuroprotection.

  2002cited by this paper
• Clinical markers of early disease in persons near onset of Huntington’s disease

  2001cited by this paper
• Improvement of Huntington's disease with olanzapine and valproate.

  2000cited by this paper
• Atypical movement disorders in the early stages of Huntington's disease: clinical and genetic analysis

  2000cited by this paper
• Bradykinesia in early Huntington’s disease

  2000cited by this paper
• Unified Huntington's disease rating scale: A follow up

  1998cited by this paper
• Juvenile Huntington disease in the Netherlands.

  1997cited by this paper
• Cortical myoclonus in huntington's disease

  1994cited by this paper
• Adult onset myoclonic Huntington's disease

  1993cited by this paper
• [Action myoclonus in adult Huntington's disease].

  1992cited by this paper
• Myoclonus in adult Huntington's disease

  1991cited by this paper
• Valproate: an updated review

  1985cited by this paper
• Myoclonus and Huntington's chorea: Description of a case

  1979cited by this paper
• Sodium valproate in Huntington's disease.

  1978cited by this paper
• Valproate sodium in Huntington chorea.

  1977cited by this paper
• Inhibitors of GABA metabolism: Implications for Huntington's disease

  1977cited by this paper
• Long‐term treatment of juvenile Huntington's chorea with dipropylacetic acid

  1977cited by this paper
• Intention myoclonus in Huntington's disease.

  1976cited by this paper
• Huntington's disease

  1976cited by this paper
• Sodium valproate in Huntington's chorea.

  1976cited by this paper
• Sodium valproate in chorea.

  1976cited by this paper

• No citing papers are available for this paper.